---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-005499"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2026-08-13T20:20:17+00:00"
generated_at: "2026-08-13T20:21:09.832655+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech reports Q3 net loss of $5.4M; advances EB06 vitiligo Phase 2

## Summary
- Q3 net loss $5.4M ($0.60/share) vs $1.7M ($0.25) year ago; nine-month loss $11.9M ($1.40) vs $5.0M ($0.95).
- R&D expenses rose $3.1M to $4.0M in Q3 on EB06 manufacturing and prep; total opex $5.5M vs $1.9M.
- Cash and equivalents $10.3M, working capital $6.9M at June 30, 2026.
- EB06 Phase 2 vitiligo study prep complete; first sites activating, recruitment to start in coming weeks in Canada.
- Paridiprubart exploratory data in ARDS with AKI showed significant mortality reduction and improved MAKE30 endpoint.

## SEC filing metadata
- accession: 0001171843-26-005499
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2026-08-13T20:20:17+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000117184326005499/0001171843-26-005499-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000117184326005499/f8k_081226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-005499
- JSON: https://secwatch.observer/filing/0001171843-26-005499.json
- Plain text: https://secwatch.observer/filing/0001171843-26-005499.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.